Browse the corpus

This activity offers an exploration of atypical antipsychotics, the preferred pharmacological intervention for acute psychoses. Distinguished by their distinct clinical profile from conventional antipsychotics, atypical antipsychotics have emerged as frontline agents in managing psychosis. This program delineates their indications, mechanism of action, administration guidelines, potential adverse effects, contraindications, toxicology considerations, and monitoring protocols. By understanding atypical antipsychotics, healthcare practitioners gain the expertise to navigate treatment complexities adeptly, thus ensuring optimal patient care and minimizing adverse reactions. Through evidence-based insights, this initiative empowers healthcare professionals to cultivate interprofessional collaboration, fostering improved treatment outcomes and bolstering patient well-being in psychiatric disorders treated with atypical antipsychotics. Objectives: Identify the indications for using atypical antipsychotic agents. Evaluate the mechanism of action of the atypical antipsychotic agents. Assess the adverse event and interaction profile for atypical antipsychotic agents. Implement interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with atypical antipsychotics, leading to optimal patient outcomes. Access free multiple choice questions on this topic.

Atypical antipsychotics block a variety of neurotransmitter receptors, which vary from one drug to another and are responsible for any toxic effects from an overdose. By blocking dopamine receptors, second-generation antipsychotics can cause extrapyramidal symptoms and neuroleptic malignant syndrome, although to a lesser extent, compared to a typical antipsychotic, eg, haloperidol. Alpha-adrenergic blockade causes orthostatic hypotension and tachycardia via vasodilation. Olanzapine, clozapine, aripiprazole, and quetiapine cause significant anti-alpha-adrenergic effects. Almost all atypical agents block serotonin receptors, and several inhibit muscarinic receptors. Quetiapine, clozapine, and olanzapine are powerful anti-muscarinic agents, and toxicity can cause urinary retention, tachycardia, hyperthermia, and delirium. Many second-generation antipsychotics also cause significant sedation by antihistamine activity; these agents are aripiprazole, quetiapine, clozapine, and olanzapine. Olanzapine causes central nervous system depression, hypotension, sedation, and sometimes agitation and is rarely lethal in monotherapy overdose. On the other hand, clozapine can sometimes be lethal in overdose by causing respiratory depression, myocarditis, cardiomyopathy, changes in heart rhythm, and altered mental status. In overdose, quetiapine is rarely fatal; however, it correlates with the highest mortality rate of all antipsychotics as it successfully blocks muscarinic, alpha-adrenergic, and histamine receptors. Toxicity with quetiapine presents with tachycardia, delirium, central nervous system depression, and rarely fatal ventricular arrhythmia. There are no reported fatalities with aripiprazole, and symptoms of overdose with ziprasidone include tachycardia, QTc prolongation, and central nervous system depression, and toxicity is seldom lethal.[40][41]

Over the past 2 decades, many novel antipsychotic agents have been developed, but there is little solid evidence to suggest that one is better than the other. The decision to choose one atypical antipsychotic over another requires clinical judgment, the patient's prior response, tolerability, affordability, and personal preferences. Plus, the adverse effects of these drugs merit consideration, as some are more likely than others to cause weight gain, dyskinesias, or sedation. The latest atypical antipsychotics are reputed to cause fewer adverse effects compared to the first generation of atypical antipsychotics, but there is no long-term data on these agents yet. All patients who receive atypical antipsychotics need to understand their adverse effects, including weight gain, prolonged QTc interval, diabetes mellitus, sedation, and the risk of dyskinesias. Patients also need to comprehend that to treat their symptoms, they must remain adherent to their drug therapy. Frequently, those individuals prescribed antipsychotics are also present with more complex management challenges. Many have other comorbidities like smoking, substance abuse, and personality disorders, all of which interfere with pharmacotherapy adherence. Most patients drop out of follow-up as soon as their symptoms improve and only return to therapy when forced by the family or the legal system.[42][43] Managing conditions with atypical antipsychotics requires an interprofessional team effort; the more eyes on patients who need these medications, the better chance for therapeutic success. While the clinician will initially prescribe one of these agents, they should consult a psychiatric specialty pharmacist, who can review the patient's medication record, assist in agent selection, and verify appropriate dosing. Nurses, clinicians, and pharmacists can offer counsel, monitor adherence, and assess for potential adverse effects of the drugs. Any mental health providers involved should also be included in the team approach, and the lines of communication among all disciplines must be open so that everyone on the interprofessional healthcare team has the same information and can offer assistance or evaluate the patient as the case progresses, leading to better patient outcomes.